Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

NCT06846541 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1680

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis
Psoriasis (PsO)
Psoriasis
Moderate Psoriasis
Severe Psoriasis

Interventions

DRUG: Open-Label Envudeucitinib
DRUG: Blinded Envudeucitinib
DRUG: Placebo

Sponsor

Alumis Inc